Medical Device

Interventional Cardiology and Peripheral Vascular Devices Market Growth, Trends and Overview for the by 2022

Posted on Updated on

Allied Market Research adds “Interventional Cardiology and Peripheral Vascular Devices Market” new report to its research database. The report provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market globally.

Interventional Cardiology and Peripheral Vascular Devices

Key players have adopted product development as their key strategy to cater to the changing needs of the industry. Major players operating in this market include Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corporation, C. R. Bard, Inc., Cardinal Health, Inc., Cook Medical, Inc., Medtronic plc, St. Jude Medical, Inc., Terumo Corporation, and The Spectranetics Corporation. As of 2015, Medtronic dominated the overall renal denervation market, followed by Abbott Laboratories and Boston Scientific Corporation.

Request sample report @

Interventional Cardiology and Peripheral Vascular Devices Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $25,349 million by 2022, registering a CAGR of 9.7% during the period 2016-2022. Angioplasty stent systems are estimated to generate the highest revenue among all segments throughout the forecast period, owing to technological advancements and development of bioabsorbable stents. North America held the leading position in the global market in 2015, and is expected to maintain its lead in the future. This is attributed to the increase in incidence of heart failures, changes in lifestyle, and high adoption of interventional cardiology and peripheral vascular devices in the region.

Send Enquiry About Report:

Growth in geriatric population, increase in prevalence of chronic diseases, changes in lifestyle of the people, technological advancements in devices, improvement of healthcare infrastructure in developing countries, development of minimally invasive procedures, and increase in patient awareness propel the market growth. However, stringent approval process for interventional cardiology and peripheral vascular devices is a major factor that hampers the market growth.

Plaque modification devices are projected to be the fastest growing segment, with a CAGR of 13.7% from 2016 to 2022, as these devices provide an efficient alternative when ballooning of arteries fail. In addition, plaque removal is also important before a stent implant as this helps in prevention of restenosis in the arteries. Apart from this, increase in incidences of plaque buildup in coronary as well as peripheral arteries and minimally invasive nature of the procedure will also drive the market.

For any Queries Connect to Analyst:

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact Us:

5933 NE Win Sivers Drive,
#205, Portland, OR 97220,
United States.
Int’l:       +1-503-894-6022
Toll Free:   +1-800-792-5285
Fax:   +1-800-792-5285

Stress is the Driving Factor of the Male Infertility Market, Takes the Market to $301.5 Million, Globally, by 2020

Posted on Updated on

Geographically, male infertility is segmented in to North America, Europe, Asia Pacific and RoW. The geographic market would be dominated by the North American region by 2020. This is due to the increased adoption of newer techniques such as DNA fragmentation in the routine analysis test for male infertility. The Asia Pacific and RoW region are expected to have the highest CAGR during the analysis period. This is due to the increase in male infertility awareness and rising awareness about the treatments that are available.


Male Infertility Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $301.5 million by 2020, registering a CAGR of 5% during the period 2014-2020.

Read more about this report:

Infertility in male is characterized by various infertility related problems such as low sperm count, presence of low motile sperm or azoospermia. The various causes of male infertility include stress, consumption of alcohol or drugs, smoking, obesity, environmental toxins, etc. These factors also act as driving factors of the male infertility market. When an individual is diagnosed with infertility, the person undergoes immense stress, embarrassment and guilt, which would further intensify the infertility problem. This is a major limitation of this market. The opportunity for the growth of this market
is the increase in awareness levels among men and rising trend in medical tourism.

The male infertility market is segmented based on techniques, namely DNA fragmentation, oxidative stress analysis, sperm agglutination test, sperm penetration test, microscopic examination, computer assisted semen analysis and others. The DNA
fragmentation would be the highest revenue generating market by 2020 and is also expected to have the highest CAGR during the analysis period, when compared to the other segments in the techniques market. This is due to the accuracy level the test provides in identifying the level of infertility by measuring the level of DNA damage.

The key companies profiled in the report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.

Male Infertility Market Segments covered in the report:

  • By Techniques

DNA Fragmentation Technique
Oxidative Stress Analysis
Microscopic Examination
Sperm Penetration Assay
Sperm Agglutination
Computer Assisted Semen Analysis

  • By Geography

North America
Asia Pacific

Continuous Glucose Monitoring (CGM) Systems Market is Expected to Reach $2,930 Million, Globally, by 2021 – Allied Market Research

Posted on

According to a new report by Allied Market Research, titled, “World Continuous Glucose Monitoring (CGM) Systems – Market Opportunities and Forecasts, 2014 -2021”, the global continuous glucose monitoring market would generate a revenue of $2,930 million by 2021, registering a CAGR of 31.3% during 2015-2021. CGM sensors accounted for about two-third share of the global CGM components market in 2014 and would continue to dominate the market until 2021. The need of active management and control of diabetes has grown considerably with growing number of diabetic population and associated cost burden. It is projected that, by 2035, the diabetes-affected patient population would reach 471 million with an associated cost burden of $627 billion. Continuous monitoring and managing glucose levels is an essential factor in diabetes management, which is primarily delivered by CGMs. In the progression, many high-tech variants of CGMs have evolved such as smartphone-connected CGMs, wearable CGMs and non-invasive CGMs. The improved efficacy and high disease prevalence has brought these devices to center stage to glucose monitoring. Increasing awareness, FDA approval to the novel and innovative products such as bionic pancreas and focus on developing CGM devices to serve new end user segment are prime drivers to the growth of CGM market. However, lack of adequate reimbursement regime for devices and clinicians, has been the key barrier to the adoption of the devices.

To view the report, visit the website at

Sensors led the market for CGM components and would also be the fastest growing segment. This growth is primarily supplemented by the recurring sales, high frequency of use, bulk purchasing and the limited life of sensors. Integrated insulin pumps would emerge as the lucrative market segment over the forecast period.

CGMS has proved to be an extremely effective tool for glucose monitoring in the Critical Care/Intensive Care Units (ICUs). Many healthcare regulatory authorities across developed and developing regions have imposed Tight Glycemic Control (TGC) protocols. Mandatory Tight Glycemic Control (TGC) protocol in ICUs will render ICUs as a lucrative customer-segment market for CGMs by 2020. The need for POC/OTC CGMs will result in the emergence of Home Healthcare as the second-most lucrative customer-segment in the CGM market.

Key findings of the study:

The North America CGM market would continue to lead CGM market throughout the forecast period, majorly due to the sustained payers’ access, better affordability and increasing confidence of CGMS among dialectologists
The ever-growing demand for POC/OTC CGM will enable Home Healthcare to be the second-most lucrative end user-segment
The Gen X demographic segment is the highly amenable for usage of CGMS
The UK CGM market would register a CAGR of 40.9% during the forecast period

Europe would be the lucrative market segment, as the CE approval process in Europe is faster and relatively easier as compared to the U.S. FDA. However, Asia-Pacific is projected to register the fastest growth mainly due to a large patient pool and rapid penetration of CGMS in emerging markets. China is considered to be the “diabetes capital” of the world by the next decade. Consequently, companies such as Medtronic and Dexcom have already expanded their distribution and supply networks in China. The enhanced supply-side infrastructure and large patient base along with increasing purchasing power would collectively make China CGM market to be the most lucrative within the Asia-Pacific.

The key companies profiled in the report are Abbott, Animas, Dexcom, Glysens, Insulet, Medtronic, Omnipod, Roche, Senseonics and Yposomed.

Global Hernia Repair Devices and Consumables Market is Expected to Reach $6.1 Billion, Globally, by 2020 – Allied Market Research

Posted on

A new report by Allied Market Research titled, “Global Hernia Repair Devices and Consumables Market – Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 2020, forecasts the market to grow at a CAGR of 6.5% during 2014 – 2020. Consumables (mesh, staple and tacks) segment would continue to be the leading segment of the global hernia repair market in 2020, largely due to the augmentation in hernia cases, recurrence rate and emergence of advanced meshes.

Increase in number of hernia repair surgeries (laparoscopy and open tension-free repair) would be the prime factor responsible for the market growth during the forecast period. As per AMR analysis, total number of hernia repair surgery was ~27 million in 2013 and is expected to reach ~36 million by 2020. Furthermore, other factors driving the market include emergence of novel meshes, technologically advanced hernia fixation devices and growing obese population. However, lack of adequate reimbursement policies and high cost associated with hernia repair procedures would restrain the market growth to a certain extent.

To view the report, visit the website at

Healthcare professionals still prefer synthetic mesh for hernia repair surgeries despite of chronic pain associated with it. However, biological meshes would be the ultimate choice for patient with high risk. Popularity of synthetic mesh is largely due to the attributes such as cost effectiveness, lesser risk of infection (less than 3%) and hard-wearing (remain permanently in the body). In case of biological mesh, it has few limitations such as risk of infection and less stronger as compared to synthetic mesh. Ongoing improvements in meshes such as absorbable, non-absorbable or partially absorbable is also a significant factor fuelling the consumables market.

Inguinal hernia is most prevalent type of hernia across the world and hence accounted for about 3/4th of the hernia repair market revenue in 2014. Geographically, North America and Europe, collectively contribute ~75% of the market share in 2013 due to increasing adoption of laparoscopic surgery and rising incidences of hernia. Asia-Pacific and LAMEA market is posed to grow at a significant pace due to increasing awareness and rising per capita expenditure on healthcare.

Key findings of the study:

  • Consumables segment is most attractive segment with faster growth and higher revenue share within hernia repair market
  • North America will remain the leading region through 2020, closely followed by Europe
  • Incisional Hernia is expected to be the fastest growing market segment during the forecast period

Key product manufacturing companies profiled in the report include Medtronic (Covidien), Ethicon, Davol, Cooper Surgicals, Cook Medicals, LifeCell Corporation, Insightra medical, B Braun Melsungen, W. L. Gore Inc. and Baxter Inc.

Global Neuroprosthetics Market is Expected to Reach $14 Billion by 2020 – Allied Market Research

Posted on

According to a new report by Allied Market Research titled, “Global Neuroprosthetics Market (Product Types, Technology, Application, and Geography) – Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013  2020“, the global neuroprosthetics market is expected to reach $14 billion by 2020, registering a CAGR of 15.8% from 2014 to 2020. High growth segments such as Visual neuroprosthetics/retinal implants and applications such as Parkinson’s disease, Overactive Bladder Syndrome and Epilepsy are expected to contribute substantially to the growth of the overall global Neuroprosthetics market. Motor Prosthetics holds the largest share within Neuroprosthetics devices market segment whereas Sacral Cord Stimulation (SCS) would maintain the leading market position through 2020, within technology segment.

To view the report, visit the website at

Multitude of cognitive and physiological disorders have a debilitating impact on ‘quality-of-life’ of affected patient populace. A majority (~80%) of such patients are unamenable to any form of treatment as first line (drug) and second line (invasive surgeries) treatments fail. Neuroprosthetics devices or neural implants or brain implants offer an efficacious solution to the afore-mentioned type of patients. Neuroprosthetics deploy technologies such as Deep Brain Simulation (DBS), Vagus Nerve Stimulation (VNS), Spinal Cord Stimulation (SCS) and Sacral Nerve Stimulation (SNS) depending on the clinical condition to ameliorate the disease condition. Depending on the condition treated, product types of Neuroprosthetics include Motor Prosthetics, Auditory Prosthetics/ Cochlear Implants, Visual Prosthetics/ Retinal implants and Cognitive Prosthetics. Owing to various factors such as high base of affected patient population, the patient population amenable to Neuroprosthetics and scope of improvement in QALY, the Motor Neuroprosthetics market for treating Parkinson’s disease garners the largest market share; Motor Neuroprosthetics for treating Overactive Bladder Syndrome and Motor Neuroprosthetics for treating Epilepsy are second and third largest segment respectively. Despite such benefits that are high-impact growth drivers for the market, high-cost of devices curtail the adoption rate by patients, thus restrain the market growth.

Key findings of the study:

  • Global market for Neuroprosthetics gaining traction with Visual Prosthetics/ Retinal implants and Motor Neuroprosthetics (for treating Parkinson’s disease) being major growth arenas during the forecast period (2014 – 2020)
  • Within Neuroprosthetics devices market, Visual Prosthetics/ Retinal implants is the fastest growing segment
  • Within Neuroprosthetics devices, Motor Neuroprosthetics segment would garner the largest market share, owing to numerous applications such as Parkinson’s disease, Neurocardiac disorders, Over Active Bladder syndrome and Epilepsy
  • North America would be the lucrative market, both in terms of market size and growth, (among all regional markets)

Neuroprosthetics manufacturing companies focus on developing variants of Neuroprosthetics devices such as self-charging neural implants that can be recharged with bioenergy; thus, eliminate the need for expensive and high-risk surgeries to replace the discharged batteries of implanted Neuroprosthetics. The companies also deploy expansion of applications as key strategy for garnering market share. Some of the key market players profiled in this report are Medtronic, Boston Scientific Corporation, St. Jude Medical, Cyberonics Inc., Retina Implant AG, MED-EL, Sonova Group (Advanced Bionics AG) and NDI Medical LLC.